Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates

This study has been terminated.
(low accrual)
Sponsor:
Collaborators:
Schering-Plough
Information provided by:
Nevada Cancer Institute
ClinicalTrials.gov Identifier:
NCT00886457
First received: April 21, 2009
Last updated: July 19, 2011
Last verified: July 2011

April 21, 2009
July 19, 2011
April 2009
August 2010   (final data collection date for primary outcome measure)
Dose limiting toxicity based on CTCAE Version 3.0 [ Time Frame: Daily for 10 days out of 14, and then weekly every 28 days ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00886457 on ClinicalTrials.gov Archive Site
Genomic DNA methylation and Mage-1 specific promoter methylation in blood cells, tumor and skin [ Time Frame: Pretreatment, and then on days 8, 15, 22, and 29 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates
Inhibition of DNA Methylation by 1-hr Infusion of 5-aza-2'-Deoxycytidine (Decitabine) x 10 Days (M-F) With Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alfa 2B (PEG-Intron): A Phase I Study With Molecular Correlates

The purpose of this study is to assess toxicities of a 1-hr infusion of 5-aza-2'-deoxycytidine (decitabine) x 10 days (M-F) plus escalating doses of weekly subcutaneous PEG-interferon-α (PEG-Intron) in patients with metastatic cancer and to identify the maximum tolerated dose of PEG-Intron in this combination. The pre- and post-treatment samples will be evaluated to identify changes in molecular correlates.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Cancer
Drug: Decitabine and Pegylated Interferon-Alfa 2B
Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
Experimental: Decitabine plus PEG Interferon-alfa 2B
3.7 mg/m**2 decitabine plus 0, 0.5, 1.5, 3, or 6 mcg/kg PET-Intron
Intervention: Drug: Decitabine and Pegylated Interferon-Alfa 2B
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
3
October 2010
August 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patient must have a biopsy proven cancer, which is metastatic or unresectable, for which (in the opinion of the investigator), no curative or more effective treatment exists.
  2. Patient must have biopsy accessible tumor and must indicate willingness to undergo biopsies of tumor and normal skin on days 1, 15 and 29.
  3. Patient must have measurable disease by RECIST criteria by scans performed within 28 days of study enrollment.
  4. Patient may not have untreated brain metastasis. Patients with previously treated brain metastasis must no longer be receiving steroid therapy for the treatment of their brain metastasis.
  5. Patient must have a Zubrod performance status of 0 - 2.
  6. Prior surgery, radiotherapy or chemotherapy is allowed. The patient must not have received chemotherapy, radiotherapy, surgery, biologic therapy or any other investigational drug for any reason within 28 days prior to registration. Concomitant treatment with other anti-cancer agents or radiotherapy, including investigational agents during the course of study treatment is not allowed.
  7. Patients with extensive pelvic irradiation or prolonged nucleoside analogue pretreatment are excluded due to increased risk for hematologic toxicity.
  8. Patient must have adequate liver function as defined by a serum bilirubin ≤ 1.5 x the institutional upper limit of normal (IULN), SGOT or SGPT ≤ 2.5 x the institutional upper limit of normal (or ≤ 5 x the institutional upper limit of normal if hepatic metastases is present) obtained within 14 days prior to registration.
  9. Patient must have an adequate renal function as defined by a serum creatinine ≤ 1.5 x the institutional upper limit of normal, as well as a calculated or measured creatinine clearance (CrCl) ≥ 50 ml/min.
  10. Patient must have an ANC > 1,500/μl, platelet count > 100,000/μl and hemoglobin > 9 gm/dl (this may be achieved by transfusion if needed) obtained within 14 days prior to registration.
  11. All patients must be informed of the investigational nature of this study and must provide written acknowledgment of informed consent in accordance with institutional and federal guidelines.
  12. Both men and women of all races and ethnic groups are eligible for this trial.
  13. Patients must be ≥ 18 years of age.

Exclusion Criteria:

  1. Class 3/4 cardiac problems as defined by the New York Heart Association Criteria (e.g., congestive heart failure, myocardial infarction within 2 months of study).
  2. Severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes, uncontrolled chronic renal or liver disease, or active uncontrolled infection, e.g., HIV).
  3. Patient must not be pregnant or nursing mothers because PEG-Intron or decitabine may be harmful to the developing fetus and newborn. Women/men of reproductive potential must agree to use an effective contraceptive method. Women of reproductive potential must have a negative serum pregnancy test within 7 days prior to registration. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
  4. Medical or psychological conditions that, in the opinion of the investigator, make the patient unable to tolerate or complete the treatment, or to grant reliable informed consent are not eligible for this study.
  5. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I, II, or III cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00886457
NVCI-0725, NCI 8224
Yes
Wolfram Samlowski, MD, Nevada Cancer Institute
Nevada Cancer Institute
  • National Institutes of Health (NIH)
  • Schering-Plough
Principal Investigator: Wolfram Samlowski, MD Nevada Cancer Institute
Nevada Cancer Institute
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP